about
Treatment for primary hypothyroidism: current approaches and future possibilitiesRituximab for thyroid-associated ophthalmopathyClinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid DiseaseGraves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and ManagementAcute thyroid eye disease (TED): principles of medical and surgical managementThe evaluation and treatment of graves ophthalmopathyFriend or foe? The current epidemiologic evidence on selenium and human cancer riskClinical Update in Aspects of the Management of Autoimmune Thyroid DiseasesA case-control study of selenoprotein genes polymorphisms and autoimmune thyroid diseases in a Chinese populationUpdate on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surfaceSelenium, selenoproteins and the thyroid gland: interactions in health and disease.Selenium and Human Health: Witnessing a Copernican Revolution?Randomized controlled trial of rituximab in patients with Graves' orbitopathyThe role of oxidative stress on the pathogenesis of graves' disease.Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.The evolving role of selenium in the treatment of graves' disease and ophthalmopathy.Alteration of Connective Tissue Growth Factor (CTGF) Expression in Orbital Fibroblasts from Patients with Graves' OphthalmopathyGeriatric thyroidology: An update.An overview of thyroid eye diseaseThe pathophysiology of thyroid eye disease: implications for immunotherapy.Inhibitory Effects of α-Lipoic Acid on Oxidative Stress-Induced Adipogenesis in Orbital Fibroblasts From Patients With Graves Ophthalmopathy.Dietary selenium and selenoprotein function.Lack of Association between Selenium Status and Disease Severity and Activity in Patients with Graves' OphthalmopathyThe 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' OrbitopathyThe protective effect of antioxidants on orbital fibroblasts from patients with Graves' ophthalmopathy in response to oxidative stress.Toward understanding success and failures in the use of selenium for cancer prevention.Advances in the management of thyroid eye diseaseSelenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trialOxidative stress in graves' disease.Oxidative Stress, Nuclear Factor-κB Pathway and Current Smoking in Graves' Ophthalmopathy.A 2016 Italian Survey about the Clinical Use of Selenium in Thyroid Disease.Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.Graves' orbitopathy: imperfect treatments for a rare disease.Methotrexate for the treatment of thyroid eye disease.Selenium and Thyroid Disease: From Pathophysiology to Treatment.The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial.Selenium supplementation in thyroid associated ophthalmopathy: an update.Thyroid eye disease: towards an evidence base for treatment in the 21st centuryTreatment options for Graves' orbitopathy.Selenium and the thyroid gland: more good news for clinicians.
P2860
Q22305857-52253616-D4C9-4595-BCF8-9E7C30F38196Q24202845-117DBED5-34D4-4443-9D32-8C2527132D94Q26749365-1EC6BA95-8C94-4515-9583-C27FF6A6513FQ26782424-F28C2A6A-C60B-4D4C-81DC-50D6F1405865Q26827429-67E97955-D6D6-4D87-9BC6-5AEB451E7DD2Q26862144-664D57D5-58F0-4950-AB5A-2552D0CC4828Q27015669-CA01C001-0DD1-4F78-8B57-D6A64A8A4B9AQ28075859-D72C2A08-8F71-4208-A63E-81CE1AB4C9E4Q33677043-F178A8AC-B8C3-4326-A1B5-C9E1B90020FCQ33802192-DDAC7011-C09B-46DA-9157-395DC3E24AD4Q34225316-3DA8796F-CD4E-4027-9B93-A56778FFFF59Q34480665-C4B8F54F-9000-42B8-A628-88B0122DC36FQ35055124-6B463B49-F968-43BC-8C83-03EF3C3BD2D0Q35607571-773D7B4D-4B30-4E35-876A-40A8228D0E23Q35617803-A0A5F282-DE59-45BF-A152-E3D74E81AD75Q35725329-248E496C-7D02-4A28-8B4B-F2C201FD7351Q35849797-EA213B9C-93CD-4732-95A9-CD759880BC68Q36107776-9FD99E95-0D2D-4BB7-A15E-BAFAFD61764BQ36305798-8F78DE43-449C-4986-AD7B-9627E8BEB33CQ36439938-4AD40272-6308-443B-BEF9-FE67C6EFD949Q36478242-118F8DD4-D4E0-4766-A774-CC6C50C4EC32Q36577265-E8473EC9-3A93-41E0-8AAE-B25F9ACA23F7Q36811270-F300B571-C692-430C-9D81-79B1BBD3F26AQ36811289-3092B39B-A484-43B5-8CE9-1E49B5B24A87Q36846603-3C2961DB-2E92-47D6-B442-90895E91F4D6Q36945715-81636ECB-E00C-4E7E-A643-D6EF70A44AE6Q37012076-9D9EA37A-1135-49ED-BB01-0FFCF5A4EDD7Q37109006-B1F49C22-F16B-450A-B32D-9F88498D48FCQ37290877-397A79B1-7918-4C2C-BEDB-9AC3D5077E6DQ37290978-B2C5CDA1-D23D-4C22-816C-8F8EB62A847CQ37387874-7D24CD9F-7556-4584-A86A-79FA3963F0E5Q37460205-4BDF1595-C133-4DDE-ACD1-2E7F5968E29BQ37582446-830AED9E-852A-4265-A24C-CE4B884B261AQ37616156-990CD61D-3DF7-4C6B-B2E4-82C0BF50C6CDQ37640141-76EF23F2-6B5F-47E6-A2EB-0FDFF2DB3CD7Q37702377-F39B7F11-F0DA-494E-BF00-245825B1C843Q37729442-EBD12448-B9F6-4FBF-9F40-F892C3089B07Q37987063-C8C8BC2A-4782-456B-9615-439D710323D2Q37992118-F1E8A967-2E57-4B32-9587-B195C75B897CQ38050459-D4D3A14C-8BF6-4901-B875-7ED8E09CFF66
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Selenium and the course of mild Graves' orbitopathy
@ast
Selenium and the course of mild Graves' orbitopathy
@en
Selenium and the course of mild Graves' orbitopathy
@nl
type
label
Selenium and the course of mild Graves' orbitopathy
@ast
Selenium and the course of mild Graves' orbitopathy
@en
Selenium and the course of mild Graves' orbitopathy
@nl
prefLabel
Selenium and the course of mild Graves' orbitopathy
@ast
Selenium and the course of mild Graves' orbitopathy
@en
Selenium and the course of mild Graves' orbitopathy
@nl
P2093
P3181
P356
P1476
Selenium and the course of mild Graves' orbitopathy
@en
P2093
Claudio Marcocci
European Group on Graves' Orbitopathy
George J Kahaly
George von Arx
Gerasimos E Krassas
Lelio Baldeschi
Luigi Bartalena
Maarten P Mourits
Maria Antonietta Altea
Mark Prummel
P304
P3181
P356
10.1056/NEJMOA1012985
P407
P577
2011-05-01T00:00:00Z